GPX2+ Tumor Cell and LGALS1+ B Cell Interactions in HBV-Positive HCC

Featuring molecular data from a single-cell analysis of Hepatitis B virus-positive hepatocellular carcinoma. It supports findings on the GPX2+ cancer stem cell population and its role in recruiting immunosuppressive LGALS1+ B cells via the CCL26-CCR3 axis. The data is provided in an XLSX file of 10.3 KB.

Use Cases

• Analyze the correlation between GPX2 expression levels and MYC or CD44 expression in cancer stem cells.
• Investigate the relationship between CCL26 signaling and the presence of LGALS1+ B cells in the tumor microenvironment.
• Model the GPX2-B cell axis as a predictor for patient outcomes in HBV-driven liver cancer.
• Examine the potential of CCR3 as a therapeutic target by correlating its activity with immunosuppressive markers.

Strengths

• Data originates from a peer-reviewed single-cell analysis study of HBV-positive HCC.
• The dataset is openly licensed under CC BY 4.0 for reuse.
• Focuses on a specific molecular mechanism (GPX2-CCL26-CCR3-LGALS1) in a defined cancer type.

Limitations

• The dataset is very small at 10.3 KB, indicating limited scope and likely a summary table rather than raw single-cell data.
• No column names, row counts, or sample data are provided, limiting immediate analytical utility.
• The data is specific to HBV-positive hepatocellular carcinoma, limiting generalizability to other cancer types or etiologies.

Provenance

Source

figshare, authored by Liang Lin.

Collection Method

Single-cell analysis from a study on HBV-positive hepatocellular carcinoma.

Freshness

Last updated March 20, 2026.